An observation of a budget impact model for third-party US payer plans showed that the model estimated a small and manageable impact for patients with penta-refractory multiple myeloma (MM) being treated with selinexor (Xpovio; Karyopharm Therapeutics, Inc). (Clinicoecon Outcomes Res. 2020 Jun 19;12:317-325. doi: 10.2147/CEOR.S251070)
In order to estimate the budgetary impact of selinexor on third-party payers in the US, a team of researchers conducted a budget impact analysis. It occurred in one-year increments for the first three years after treatment was initiated for a private payer or Medicare Part D. They calculated total annual treatment costs based on the combination of drug costs, costs of adverse events (AEs; grade ≥ 3), along with ongoing best supportive care costs.
The study authors used a base-case analysis and a scenario analysis for their study. According to the findings of the base-case analysis, treatment with selinexor was linked to a per member per month (PMPM) cost of $0.0103 in year 3, assuming a market uptake of 64%. They study authors highlighted that this was for a hypothetical private payer plan with one million members and four eligible patients.
For the scenario analysis, they identified 16 eligible patients with triple-class refractory MM regardless of the line of therapy. The estimated PMPM cost for this analysis in year 3 was $0.0388.
The study authors noted that the base-case analysis that was conducted from the Medicare Part D perspective had an associated PMPM cost of $0.0078 in year 3 that was identified with 159 eligible patients.
According to the findings, the budget impact model had comparable sensitivity to treatment duration. Additionally, it showed the same sensitivity to wholesale acquisition cost for selinexor, as well as year 1 uptake.
“The model estimates a small and manageable budget impact of adopting selinexor into a third-party US payer plan, given the low prevalence of penta-refractory MM,” they concluded.—Julie Gould
